Persistent high NTpro-BNP concentration as a negative prognostic factor in patients with decompensated heart failure

Kardiologia Polska

Volumn 64, Issue 3, 2006, Pages 250-256

  Kübler, Piotr ^a   Petruk Kowalczyk, Jolanta ^a   Majda, Jacek ^a   Reczuch, Krzysztof ^a   Banasiak, Waldemar ^a   Ponikowski, Piotr ^a  

^a 4TH MILITARY HOSPITAL   (Poland)

Author keywords

Brain natriuretic peptide; Congestive heart failure; Prognosis

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; BREATHING RATE; CLINICAL FEATURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEALTH STATUS; HEART FAILURE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE;

EID: 33747334916     PISSN: 00229032     EISSN: 00229032     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Stewart S, MacIntyre K, Hole DJ, et al. More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001; 3: 315-22.
2. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347: 1397-402.
3. Ho KK, Pinsky JL, Kannel WB, et al. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993; 22(4 Suppl. A): 6A-13A.
4. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90: 195-203.
5. Mair J, Hammerer-Lercher A, Puschendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 2001; 39: 571-88.
6. McClure SJ, Caruana L, Davie AP, et al. Cohort study of plasma natriuretic peptides for identifying left ventricular systolic dysfunction in primary care. BMJ 1998; 317: 516-9.
7. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351: 9-13.
8. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350: 1349-53.
9. Richards AM, Nicholls MG, Yandle TG, et al. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. The Christchurch Cardioendocrine Research Group. Heart 1999; 81: 114-20.
10. Maeda K, Tsutamoto T, Wada A, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000; 36: 1587-93.
11. Stanek B, Frey B, Hulsmann M, et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 2001; 38: 436-42.
12. Doggrell SA. Brain natriuretic peptide: Disease marker or more in cardiovascular medicine? Drugs Today (Barc). 2001; 37: 463-76.
13. Holmes SJ, Espiner EA, Richards AM, et al. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab 1993; 76: 91-6.
14. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001; 37: 386-91.
15. Gackowski A, Isnard R, Golmard JL, et al. Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure. Eur Heart J 2004; 25: 1788-96.
16. Ishii J, Nomura M, Nakamura Y, et al. Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am J Cardiol 2002; 89: 691-5.
17. Yu CM, Sanderson JE. Plasma brain natriuretic peptide-an independent predictor of cardiovascular mortality in acute heart failure. Eur J Heart Fail 1999; 1: 59-65.
18. Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 2004; 43: 635-41.
19. Wu AH, Smith A, Apple FS. Optimum blood collection intervals for B-type natriuretic peptide testing in patients with heart failure. Am J Cardiol 2004; 93: 1562-3.
20. Hobbs RE. Using BNP to diagnose, manage, and treat heart failure. Cleve Clin J Med 2003; 70: 333-6.